
If everything goes well with the development of Pellepharm’s treatment for Gorlin syndrome, patidegib, the company will launch the drug in 2022. With this time frame in mind, the company’s Danish partner, Leo Pharma, has now assembled a team to help the small, San Francisco-based company with its launch plans.
This is despite the fact that Leo Pharma has not yet decided whether to use the option agreement it has with Pellepharm to buy the company.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app